Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging
Abstract AGuIX, a novel gadolinium-based nanoparticle, has been deployed in a pioneering double-blinded Phase II clinical trial aiming to assess its efficacy in enhancing radiotherapy for tumor treatment. This paper moves towards this goal by analyzing AGuIX uptake patterns in 23 patients. A phantom...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-62389-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850251796135542784 |
|---|---|
| author | Stephanie Bennett Camille Verry Evangelia Kaza Xin Miao Sandrine Dufort Fabien Boux Yannick Crémillieux Olivier de Beaumont Géraldine Le Duc Ross Berbeco Atchar Sudhyadhom |
| author_facet | Stephanie Bennett Camille Verry Evangelia Kaza Xin Miao Sandrine Dufort Fabien Boux Yannick Crémillieux Olivier de Beaumont Géraldine Le Duc Ross Berbeco Atchar Sudhyadhom |
| author_sort | Stephanie Bennett |
| collection | DOAJ |
| description | Abstract AGuIX, a novel gadolinium-based nanoparticle, has been deployed in a pioneering double-blinded Phase II clinical trial aiming to assess its efficacy in enhancing radiotherapy for tumor treatment. This paper moves towards this goal by analyzing AGuIX uptake patterns in 23 patients. A phantom was designed to establish the relationship between AGuIX concentration and longitudinal ( $${T}_{1}$$ T 1 ) relaxation. A 3T MRI and MP2RAGE sequence were used to generate patient $${T}_{1}$$ T 1 maps. AGuIX uptake in tumors was determined based on longitudinal relaxivity. AGuIX (or placebo) was administered to 23 patients intravenously at 100 mg/kg 1–5 hours pre-imaging. Each of 129 brain metastases across 23 patients were captured in $${T}_{1}$$ T 1 maps and examined for AGuIX uptake and distribution. Inferred AGuIX recipients had average tumor uptakes between 0.012 and 0.17 mg/ml, with a mean of 0.055 mg/ml. Suspected placebo recipients appeared to have no appreciable uptake. Tumors presented with varying spatial AGuIX uptake distributions, suspected to be related to differences in accumulation time and patient-specific bioaccumulation factors. This research demonstrates AGuIX's ability to accumulate in brain metastases, with quantifiable uptake via $${T}_{1}$$ T 1 mapping. Future analyses will extend these methods to complete clinical trial data (~ 134 patients) to evaluate the potential relationship between nanoparticle uptake and possible tumor response following radiotherapy. Clinical Trial Registration Number: NCT04899908. Clinical Trial Registration Date: 25/05/2021. |
| format | Article |
| id | doaj-art-293759d42a3e475ba20a25ec8fdc98f8 |
| institution | OA Journals |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-293759d42a3e475ba20a25ec8fdc98f82025-08-20T01:57:49ZengNature PortfolioScientific Reports2045-23222024-05-0114111110.1038/s41598-024-62389-1Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imagingStephanie Bennett0Camille Verry1Evangelia Kaza2Xin Miao3Sandrine Dufort4Fabien Boux5Yannick Crémillieux6Olivier de Beaumont7Géraldine Le Duc8Ross Berbeco9Atchar Sudhyadhom10Brigham and Women’s Hospital|Dana-Farber Cancer Institute|Harvard Medical SchoolUniversité Grenoble Alpes, CHU Grenoble Alpes, Service de Radiothérapie, Inserm UA7Brigham and Women’s Hospital|Dana-Farber Cancer Institute|Harvard Medical SchoolSiemens Medical Solutions USA Inc.NH TherAguix SANH TherAguix SANH TherAguix SANH TherAguix SANH TherAguix SABrigham and Women’s Hospital|Dana-Farber Cancer Institute|Harvard Medical SchoolBrigham and Women’s Hospital|Dana-Farber Cancer Institute|Harvard Medical SchoolAbstract AGuIX, a novel gadolinium-based nanoparticle, has been deployed in a pioneering double-blinded Phase II clinical trial aiming to assess its efficacy in enhancing radiotherapy for tumor treatment. This paper moves towards this goal by analyzing AGuIX uptake patterns in 23 patients. A phantom was designed to establish the relationship between AGuIX concentration and longitudinal ( $${T}_{1}$$ T 1 ) relaxation. A 3T MRI and MP2RAGE sequence were used to generate patient $${T}_{1}$$ T 1 maps. AGuIX uptake in tumors was determined based on longitudinal relaxivity. AGuIX (or placebo) was administered to 23 patients intravenously at 100 mg/kg 1–5 hours pre-imaging. Each of 129 brain metastases across 23 patients were captured in $${T}_{1}$$ T 1 maps and examined for AGuIX uptake and distribution. Inferred AGuIX recipients had average tumor uptakes between 0.012 and 0.17 mg/ml, with a mean of 0.055 mg/ml. Suspected placebo recipients appeared to have no appreciable uptake. Tumors presented with varying spatial AGuIX uptake distributions, suspected to be related to differences in accumulation time and patient-specific bioaccumulation factors. This research demonstrates AGuIX's ability to accumulate in brain metastases, with quantifiable uptake via $${T}_{1}$$ T 1 mapping. Future analyses will extend these methods to complete clinical trial data (~ 134 patients) to evaluate the potential relationship between nanoparticle uptake and possible tumor response following radiotherapy. Clinical Trial Registration Number: NCT04899908. Clinical Trial Registration Date: 25/05/2021.https://doi.org/10.1038/s41598-024-62389-1 |
| spellingShingle | Stephanie Bennett Camille Verry Evangelia Kaza Xin Miao Sandrine Dufort Fabien Boux Yannick Crémillieux Olivier de Beaumont Géraldine Le Duc Ross Berbeco Atchar Sudhyadhom Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging Scientific Reports |
| title | Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging |
| title_full | Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging |
| title_fullStr | Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging |
| title_full_unstemmed | Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging |
| title_short | Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging |
| title_sort | quantifying gadolinium based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging |
| url | https://doi.org/10.1038/s41598-024-62389-1 |
| work_keys_str_mv | AT stephaniebennett quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT camilleverry quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT evangeliakaza quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT xinmiao quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT sandrinedufort quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT fabienboux quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT yannickcremillieux quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT olivierdebeaumont quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT geraldineleduc quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT rossberbeco quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging AT atcharsudhyadhom quantifyinggadoliniumbasednanoparticleuptakedistributionsinbrainmetastasesviamagneticresonanceimaging |